{"contentid": 488760, "importid": NaN, "name": "Myfembree approved for heavy menstrual bleeding associated with uterine fibroids", "introduction": "Myovant Sciences and Pfizer have announced that the US Food and Drug Administration (FDA) has approved Myfembree (relugolix/estradiol/norethindrone acetate), the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.", "content": "<p>Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) have announced that the US Food and Drug Administration (FDA) has approved Myfembree (relugolix/estradiol/norethindrone acetate), the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.</p>\n<p>Under the terms of their previously announced collaboration, Myovant and Pfizer will jointly commercialize the product in the USA. The tablet is expected to be available next month.</p>\n<p><span class=\"pullQuote\">\"The approval of Myfembree represents the second FDA product approval for Myovant in less than one year\"</span>Ayman Al-Hendy, professor of obstetrics and gynecology, University of Chicago, and LIBERTY Program steering committee member, said: &ldquo;With Myfembree, we can offer women with uterine fibroids a non-invasive treatment that provides clinically-meaningful symptom relief for heavy menstrual bleeding with one pill, once-a-day.</p>\n<p>&ldquo;The FDA approval of Myfembree represents a significant milestone in expanding treatment options for uterine fibroids, a chronic and debilitating disease for many women in the USA.&rdquo;</p>\n<p>David Marek is chief executive of Myovant, which is majority-owned by the Sumitomo Dainippon Pharma (TYO: 4506) subsidiary Sumitovant Biopharma. Shares in the company closed 4% higher on Wednesday.</p>\n<p>He said: &ldquo;Uterine fibroids affect millions of women in the USA and account for over 250,000 hysterectomies each year, with heavy menstrual bleeding being one of the most bothersome symptoms.</p>\n<p>&ldquo;The approval of Myfembree represents the second FDA product approval for Myovant in less than one year. This is an important step forward as we seek to redefine care for women and for men, not only through new medicines but through continued collaboration with the community.&rdquo;</p>\n<p>&nbsp;</p>", "date": "2021-05-27 14:06:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-27 12:41:34", "updated": "2021-05-27 14:10:23", "access": NaN, "url": "https://www.thepharmaletter.com/article/myfembree-approved-for-heavy-menstrual-bleeding-associated-with-uterine-fibroids", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "myovant_sciences.png", "image2id": "myovant_sciences_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Uterine fibroids", "sector_tag": "Pharmaceutical", "therapy area_tag": "Women's health", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "USA", "company_tag": "Myovant Sciences, Pfizer", "drug_tag": "Myfembree", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-27 14:06:00"}